TABLE 2.
Results of the statistical analysis: association with PFS and survival.
| Univariate proportional hazard model | ||||||
| Variable |
Progression free survival
|
Overall survival
|
||||
| N | HR (95% CI) | p-value | N | HR (95% CI) | p-value | |
|
| ||||||
| Age | 16 | 1.1 (1–1.1) | 0.054 | 20 | 1 (0.99–1.1) | 0.13 |
| Sex | 16 | 0.58 (0.19–1.8) | 0.34 | 20 | 0.77 (0.29–2.1) | 0.6 |
| KPI | 16 | 0.96 (0.92–1) | 0.11 | 19 | 0.98 (0.94–1) | 0.19 |
| MGMT status | 12 | 0.96 (0.25–3.7) | 0.95 | 14 | 0.99 (0.3–3.3) | 0.98 |
| Recurrence | 16 | 1.7 (0.57–5.1) | 0.33 | 20 | 1.6 (0.65–4.2) | 0.3 |
| Resection | 16 | 2.1 (0.71–6.0) | 0.18 | 20 | 2.4 (0.94–6.2) | 0.07 |
| CRT | 16 | 0.31 (0.1–1) | 0.046 | 20 | 0.41 (0.16–1.1) | 0.07 |
| Response (RANO) | 16 | 0.02 (10–4−0.21)* | 6.6⋅10 – 5* | 16 | 0.17 (0.04–0.65) | 0.005 |
| Response (3T MRI w/o clinical data) | 16 | 0.1 (0.02–0.49) | 0.0009 | 16 | 0.26 (0.08–0.87) | 0.02 |
| TSC Median t0 | 16 | 0.98 (0.92–1.1) | 0.62 | 20 | 1 (0.95–1.1) | 0.85 |
| TSC Δ t1–t0 | 14 | 0.97 (0.92–1) | 0.27 | 14 | 0.97 (0.93–1) | 0.24 |
| TSC Δ t2–t0 | 10 | 1 (0.98–1) | 0.83 | 10 | 0.99 (0.98–1) | 0.51 |
| TSC Δ t2–t1 | 10 | 1 (0.99–1.1) | 0.25 | 10 | 1 (0.97–1) | 0.96 |
N, number of patients; HR, hazard ratio; CI, confidence interval; KPI, Karnofsky Performance Index; MGMT, O6-methylguanine DNA methyltransferase; CRT, chemoradiotherapy; TSC, tissue sodium concentration; Δ, relative TSC difference; t0, pre-therapy 23Na MRI; t1, 23Na MRI immediately post-therapy; t2, 23Na MRI 6-weeks post-therapy.
*The corresponding analysis was based on Firth’s penalized likelihood method with the computation of profile likelihood confidence intervals and p-values according to penalized likelihood ratio tests.
Bold indicates statistically significant values with p < 0.05.